miR‑96 induces cisplatin chemoresistance in non‑small cell lung cancer cells by downregulating SAMD9

Wu,Lin; Pu,Xingxiang; Wang,Qianzhi; Cao,Jun; Xu,Fang; Xu,Li; Li,Kang

doi:10.3892/ol.2015.4000

February-2016 Volume 11 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2016 Volume 11 Issue 2

Full Size Image

Article Open Access

miR‑96 induces cisplatin chemoresistance in non‑small cell lung cancer cells by downregulating SAMD9

Authors:
- Lin Wu
- Xingxiang Pu
- Qianzhi Wang
- Jun Cao
- Fang Xu
- Li Xu
- Kang Li
View Affiliations / Copyright

Affiliations: Department of Thoracic Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410003, P.R. China

Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 945-952
|
Published online on: December 3, 2015

https://doi.org/10.3892/ol.2015.4000
Expand metrics +

Abstract

Cisplatin is effective as a single agent or in combination with other drugs for the treatment of non‑small cell lung cancer (NSCLC). A concerning clinical challenge with cisplatin‑based NSCLC chemotherapy is the intrinsic and acquired chemoresistance to cisplatin. The sterile α motif domain‑containing (SAMD9) gene has been reported as a potent tumor suppressor gene that inhibits tumorigenesis and progression of NSCLC. microRNAs (miRNA) have been revealed to play important roles in the regulation of cancer chemoresistance. To the best of our knowledge the present study explored the role of miRNA/SAMD9 signaling in regulating cisplatin chemoresistance in NSCLC for the first time. Out of the several candidate miRNAs predicted to bind the 3'‑untranslated region (UTR) of the SAMD9 gene, miRNA‑96 (miR‑96) demonstrated significant target‑sequence‑specific inhibition of the SAMD9 3'‑UTR luciferase reporter activity in NSCLC cells. In addition, while NSCLC tumor samples exhibited significantly higher expression levels of miR‑96 compared with adjacent normal tissues, the expression levels of SAMD9 were significantly lower than those in adjacent normal tissues. miR‑96 and SAMD9 were overexpressed and knocked down in the human NSCLC H358 and H23 cell lines and the half maximal inhibitory concentration (IC50) of cisplatin and cell apoptosis rate under cisplatin treatment were used as measures of cisplatin chemoresistance. The present results identified that overexpression of miR‑96 in NSCLC cells markedly decreased SAMD9 expression and cisplatin‑induced apoptosis, and increased the cisplatin IC50, which could be eliminated by overexpression of SAMD9. By contrast, knocking down miR‑96 in NSCLC cells using antagomir‑96 significantly increased SAMD9 expression and the cisplatin‑induced apoptosis and decreased cisplatin IC50, which could be completely reversed by a knockdown of SAMD9. In conclusion, the current study demonstrates that miR‑96 targets and downregulates SAMD9 in NSCLC, which decreases cisplatin‑induced apoptosis and induces cisplatin chemoresistance in NSCLC cells. The findings of the present study add novel insights into the function of miR‑96 and SAMD9 in cancer, as well as into the molecular mechanisms underlying NSCLC chemoresistance.

View Figures

View References

1	Ma L, Huang Y, Zhu W, et al: An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PLoS One. 6:e265022011. View Article : Google Scholar : PubMed/NCBI
2	Merk J, Rolff J, Dorn C, Leschber G and Fichtner I: Chemoresistance in non-small-cell lung cancer, Can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg. 40:e29–e33. 2011. View Article : Google Scholar : PubMed/NCBI
3	Chang A: Chemotherapy chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10. 2011. View Article : Google Scholar : PubMed/NCBI
4	Asou H, Matsui H, Ozaki Y, et al: Identification of a common microdeletion cluster in 7q21.3 subband among patients with myeloid leukemia and myelodysplastic syndrome. Biochem Biophys Res Commun. 383:245–251. 2009. View Article : Google Scholar : PubMed/NCBI
5	Li CF, MacDonald JR, Wei RY, et al: Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse. BMC Genomics. 8:922007. View Article : Google Scholar : PubMed/NCBI
6	Ma Q, Yu T, Ren YY, Gong T and Zhong DS: Overexpression of SAMD9 suppresses tumorigenesis and progression during non small cell lung cancer. Biochem Biophys Res Commun. 454:157–161. 2014. View Article : Google Scholar : PubMed/NCBI
7	Feng B, Wang R and Chen LB: Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother. 66:397–402. 2012. View Article : Google Scholar : PubMed/NCBI
8	Van Den Broeck A, Ozenne P, Eymin B and Gazzeri S: Lung cancer, A modified epigenome. Cell Adh Migr. 4:107–113. 2010. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Filipowicz W, Jaskiewicz L, Kolb FA and Pillai RS: Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol. 15:331–341. 2005. View Article : Google Scholar : PubMed/NCBI
11	Byun K, Bayarsaikhan E, Kim CY, Mook-Jung I, Paek SH, Kim SU, Yamamoto T, Won MH, Song BJ, et al: Induction of neuronal death by microglial AGE-albumin: Implications for Alzheimer's disease. PLoS ONE. 7:e379172012. View Article : Google Scholar : PubMed/NCBI
12	Garcia DM, Baek D, Shin C, Bell GW, Grimson A and Bartel DP: Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
13	Liu M, Wang J, Huang H, Hou J, Zhang B and Wang A: miR-181a-Twist1 pathway in the chemoresistance of tongue squamous cell carcinoma. Biochem Biophys Res Commun. 441:364–370. 2013. View Article : Google Scholar : PubMed/NCBI
14	Xia H, Chen S, Chen K, Huang H and Ma H: MiR-96 promotes proliferation and chemo- or radioresistance by down-regulating RECK in esophageal cancer. Biomed Pharmacother. 68:951–958. 2014. View Article : Google Scholar : PubMed/NCBI
15	Li J, Li P, Chen T, Gao G, Chen X, Du Y, Zhang R, Yang R, Zhao W, Dun S, Gao F, et al: Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer. Tumour Biol. 36:685–692. 2015. View Article : Google Scholar : PubMed/NCBI
16	Feng J, Yu J, Pan X, Li Z, Chen Z, Zhang W, Wang B, Yang L, Xu H, Zhang G and Xu Z: HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Oncotarget. 5:5832–5844. 2014. View Article : Google Scholar : PubMed/NCBI
17	Rosenberg B, VanCamp L, Trosko JE and Mansour VH: Platinum compounds, A new class of potent antitumour agents. Nature. 222:385–386. 1969. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

miR‑96 induces cisplatin chemoresistance in non‑small cell lung cancer cells by downregulating SAMD9

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Related Articles